Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
European Psychiatry : the Journal of the Association of European Psychiatrists
|
August 25, 2009
Pharmacotherapy of dysthymia: review and new findings
M Versiani, A E Nardi, I Figueira
The Journal of Neuropsychiatry and Clinical Neurosciences
|
December 19, 2001
Impaired set-shifting ability and therapeutic response in obsessive-compulsive disorder
L Fontenelle, C Marques, E Engelhardt, et al.
The Journal of Clinical Psychiatry
|
July 13, 1999
Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder
M Versiani, L Mehilane, P Gaszner, et al.
The Journal of International Medical Research
|
January 1, 1980
Loxapine versus thioridazine in the treatment of organic psychosis
M Versiani, J A da Silva, F D Mundim
Acta Psychiatrica Scandinavica. Supplementum
|
January 1, 1990
Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo
M Versiani, A E Nardi, I L Figueira, et al.
Journal of Neural Transmission. Supplementum
|
January 1, 1989
Moclobemide, imipramine, and placebo in the treatment of major depression (DSM III)
M Versiani, A E Nardi, F D Mundim, et al.
Journal of Clinical Psychopharmacology
|
August 1, 1988
Tranylcypromine in social phobia
M Versiani, F D Mundim, A E Nardi, et al.
Journal of Affective Disorders
|
January 11, 2000
Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial
C Katona, E Bercoff, E Chiu, et al.
Arquivos De Neuro-Psiquiatria
|
August 2, 2000
Neuropsychological sequelae in Kleine-Levin syndrome: case report
L Fontenelle, M V Mendlowicz, J C Gillin, et al.
Acta Psychiatrica Scandinavica. Supplementum
|
January 1, 1990
Moclobemide, imipramine and placebo in the treatment of major depression
M Versiani, A E Nardi, F D Mundim, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
European Psychiatry : the Journal of the Association of European Psychiatrists
|
August 25, 2009
Pharmacotherapy of dysthymia: review and new findings
M Versiani, A E Nardi, I Figueira
The Journal of Neuropsychiatry and Clinical Neurosciences
|
December 19, 2001
Impaired set-shifting ability and therapeutic response in obsessive-compulsive disorder
L Fontenelle, C Marques, E Engelhardt, et al.
The Journal of Clinical Psychiatry
|
July 13, 1999
Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder
M Versiani, L Mehilane, P Gaszner, et al.
The Journal of International Medical Research
|
January 1, 1980
Loxapine versus thioridazine in the treatment of organic psychosis
M Versiani, J A da Silva, F D Mundim
Acta Psychiatrica Scandinavica. Supplementum
|
January 1, 1990
Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo
M Versiani, A E Nardi, I L Figueira, et al.
Journal of Neural Transmission. Supplementum
|
January 1, 1989
Moclobemide, imipramine, and placebo in the treatment of major depression (DSM III)
M Versiani, A E Nardi, F D Mundim, et al.
Journal of Clinical Psychopharmacology
|
August 1, 1988
Tranylcypromine in social phobia
M Versiani, F D Mundim, A E Nardi, et al.
Journal of Affective Disorders
|
January 11, 2000
Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial
C Katona, E Bercoff, E Chiu, et al.
Arquivos De Neuro-Psiquiatria
|
August 2, 2000
Neuropsychological sequelae in Kleine-Levin syndrome: case report
L Fontenelle, M V Mendlowicz, J C Gillin, et al.
Acta Psychiatrica Scandinavica. Supplementum
|
January 1, 1990
Moclobemide, imipramine and placebo in the treatment of major depression
M Versiani, A E Nardi, F D Mundim, et al.
Page
of 4